Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn ’s Disease
ConclusionParenteral MTX proved to be cost-effective in patients with mild-to-moderate CD. This is the first published cost-effectiveness analysis of pMTX for this indication. It also shows an example of a lack of valuation of generic therapy despite its cost-effectiveness and a clear benefit to the healthcare system.
Source: Applied Health Economics and Health Policy - Category: Health Management Source Type: research
More News: Clinical Trials | Corticosteroid Therapy | Crohn's Disease | Czechia Health | Economics | Health Management | Methotrexate